XASX
ADO
Market cap31mUSD
Oct 09, Last price
0.02AUD
1D
7.14%
1Q
-46.43%
Jan 2017
-61.72%
IPO
-99.50%
Name
Anteotech Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Key people
Glenda McLoughlin
Independent Non-Executive Chairman of the Board · since 2025
Interim Chief Financial Officer, Company Secretary · since 2026
Katrina Byrne
Chief Operating Officer · since 2022
Tsui Min Lian
Chief Marketing Officer · since 2023
Nobuyoshi Maeji
Chief Scientific Officer · since 2009
Andrew Cook
Chief Financial Officer, Company Secretary · since 2023
Merrill Gray
Chief Executive Officer, Managing Director, Director · since 2025
Non-Executive Independent Director · since 2022
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||